Could a diabetes drug boost radiation to fight returning prostate cancer?

NCT ID NCT04536805

Ongoing Disease control Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for men whose prostate cancer has returned in the same area after they already had radiation and surgery. The researchers want to see if giving a very precise, high-dose radiation treatment (called SBRT) along with the diabetes drug metformin can safely control the cancer again. About 44 participants will receive different radiation doses to find the best one. The study will track PSA levels for up to 5 years to see how well the treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

CHRU de BREST - HOPITAL MORVAN

Brest, 29200, France
Centre Eugene Marquis

Rennes, 35042, France
Centre GEORGES FRANCOIS LECLERC

Dijon, 21079, France
Centre Henri Becquerel

Rouen, 76038, France
Centre LEON BERARD

Lyon, 69373, France
Centre OSCAR LAMBRET

Lille, 59020, France
Chru Bretonneau

Tours, 37044, France
Clinique Victor Hugo

Le Mans, 72100, France
ICANS - Institut de cancérologie Strasbourg Europe

Strasbourg, 67200, France
Institut de Cancerologie de L'Ouest

Angers, 49055, France
Institut de Cancerologie de L'Ouest

Saint-Herblain, 44805, France
Societe de Recherche Oncologique Clinique 37 (Roc 37)

Chambray-lès-Tours, 37170, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.